Intellia Therapeutics, Inc. (NASDAQ:NTLA) to Post FY2026 Earnings of ($4.98) Per Share, Wedbush Forecasts

Intellia Therapeutics, Inc. (NASDAQ:NTLAGet Rating) – Equities researchers at Wedbush issued their FY2026 earnings estimates for shares of Intellia Therapeutics in a research report issued on Wednesday, August 3rd. Wedbush analyst D. Nierengarten forecasts that the company will earn ($4.98) per share for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.77) per share.

Other analysts also recently issued research reports about the stock. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a report on Friday. Credit Suisse Group started coverage on shares of Intellia Therapeutics in a research note on Thursday, April 28th. They issued an “outperform” rating and a $100.00 price objective for the company. Bank of America started coverage on shares of Intellia Therapeutics in a research note on Thursday, June 16th. They issued a “buy” rating and a $70.00 price objective for the company. The Goldman Sachs Group dropped their price objective on shares of Intellia Therapeutics from $206.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, May 24th. Finally, BMO Capital Markets started coverage on shares of Intellia Therapeutics in a research note on Thursday, June 16th. They issued a “market perform” rating and a $54.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, Intellia Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $131.06.

Intellia Therapeutics Trading Down 3.2 %

Shares of Intellia Therapeutics stock opened at $63.32 on Friday. The company has a 50 day moving average of $55.42 and a 200-day moving average of $64.22. Intellia Therapeutics has a 1-year low of $37.08 and a 1-year high of $180.59. The company has a market cap of $4.80 billion, a PE ratio of -12.59 and a beta of 2.00.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.03). Intellia Therapeutics had a negative return on equity of 41.00% and a negative net margin of 973.48%. The firm had revenue of $14.00 million for the quarter, compared to the consensus estimate of $9.50 million. During the same period last year, the company posted ($1.01) EPS. The business’s revenue was up 115.4% on a year-over-year basis.

Institutional Investors Weigh In On Intellia Therapeutics

Several large investors have recently modified their holdings of the company. ARK Investment Management LLC grew its holdings in Intellia Therapeutics by 13.4% in the first quarter. ARK Investment Management LLC now owns 8,981,029 shares of the company’s stock worth $652,651,000 after purchasing an additional 1,064,147 shares during the period. Viking Global Investors LP lifted its stake in shares of Intellia Therapeutics by 56.3% in the first quarter. Viking Global Investors LP now owns 2,468,760 shares of the company’s stock valued at $179,405,000 after buying an additional 889,224 shares in the last quarter. State Street Corp lifted its stake in shares of Intellia Therapeutics by 30.2% in the first quarter. State Street Corp now owns 2,397,527 shares of the company’s stock valued at $174,228,000 after buying an additional 556,076 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of Intellia Therapeutics by 14.7% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,753,903 shares of the company’s stock valued at $325,621,000 after buying an additional 353,970 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. lifted its stake in shares of Intellia Therapeutics by 14.7% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 2,753,903 shares of the company’s stock valued at $327,714,000 after buying an additional 353,970 shares in the last quarter. 85.89% of the stock is currently owned by institutional investors and hedge funds.

About Intellia Therapeutics

(Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Featured Stories

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.